Metrika

  • citati u SCIndeksu: [6]
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:12
  • preuzimanja u poslednjih 30 dana:5

Sadržaj

članak: 6 od 28  
Back povratak na rezultate
2015, vol. 72, br. 9, str. 813-822
Odnos koncentracije i doze takrolimusa kao strategija terapijskog monitoringa leka - uticaj pola i komedikacije
aVojnomedicinska akademija, Centar za kliničku farmakologiju, Beograd, Srbija + Univerzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd, Srbija
bUniverzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd, Srbija + Vojnomedicinska akademija, Centar za transplantaciju solidnih organa, Beograd, Srbija
cUniverzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd, Srbija + Vojnomedicinska akademija, Beograd, Srbija
dUniverzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd, Srbija + Vojnomedicinska akademija, Institut za medicinska istraživanja, Beograd, Srbija
eUniverzitet u Novom Sadu, Medicinski fakultet, Zavod za farmakologiju, toksikologiju i kliničku farmakologiju, Srbija

e-adresanece84@hotmail.com
Projekat:
Analiza strukture troškova i uticaja na zdravstveni budžet Republike Srbije epidemiološki najmasovnijih i/ili najskupljih oboljenja i procena odnosa troškovi / efektivnost / korisnost medicinskih intervencija (MPNTR - 175014)
Analiza genskih polimorfirzama CIP izoenzima u populaciji Srbije (MPNTR - 175093)

Sažetak
Uvod/Cilj. Kombinacija takrolimusa i drugih lekova kao što su kortikosteroidi, čest je imunosupresivni režim. S druge strane, raste broj dokaza da se muškarci i žene mogu razlikovati u odgovoru na lečenje istim lekom. Cilj ovog rada bio je da se proceni uticaj razlike među polovima i komedikacije na izloženost takrolimusu, uz pomoć odnosa koncentracije i doze (C/D odnos) takrolimusa kod bolesnika sa transplantiranim bubregom. Metode. Ispitivanje je sprovedeno kroz prospektivnu seriju od 54 bolesnika, gde je jedinica posmatranja bio kontrolni ambulantni pregled (1 872) bolesnika sa transplantiranim bubregom. Bolesnici su praćeni od 2010. do 2014. godine, a praćenje je započeto mesec dana nakon transplantacije. Minimalna koncentracija takrolimusa u krvi (tacrolimus trough concentration - TTC) merena je uz pomoć hemiluminiscentnog mikročestičnog imunoeseja. Rezultati. Odnos TTC i C/D bio je značajno niži kod žena nego kod muškaraca. Za razliku od muškaraca, kod žena je nađeno značajno povećanje dnevne doze takrolimusa (TDD) po kg telesne težine i TTC, zajedno sa povećanjem doze kortikosteroida, koje nije bilo praćeno značajnim promenama odnosa C/D. Bolesnici koji su upotrebljavali inhibitore protonske pumpe (većinom pantoprazol), imali su značajno viši TDD po kg telesne težine i TTC, dok je odnos C/D bio značajno niži nego kod bolesnika bez ovog tretmana. Kod bolesnika koji su upotrebljavali blokatore kalcijumovih kanala (pogotovo amlodipina) TDD po kg telesne težine bio je značajno niži, dok je odnos C/D bio značajno viši nego kod bolesnika bez ovog tretmana. Zaključak. Rezultati pokazuju da su žene manje izložene takrolimusu nego muškarci. Kada su posmatrane polne razlike u odnosu na različite doze kortikosteroida, utvrđeno je brže eliminisanje takrolimusa kod žena, osim kada je doza kortikosteroida bila > 0,25 mg/kg. Izloženost takrolimusu u prisustvu pantoprazola bila je značajno manje izražena, dok je u prisustvu amlodipina bila značajno viša nego kod bolesnika koji nisu bili lečeni ovim lekovima.
Reference
Anderson, G.D. (2008) Gender differences in pharmacological response. Int Rev Neurobiol, 83: 1-10
Anglicheau, D., Flamant, M., Schlageter, M.H., Martinez, F., Cassinat, B., Beaune, P., Legendre, C., Thervet, E. (2003) Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrology, dialysis, transplantation, 18(11): 2409-14
Barraclough, K.A., Isbel, N.M., Kirkpatrick, C.M., Lee, K.J., Taylor, P.J., Johnson, D.W., Campbell, S.B., Leary, D.R., Staatz, C.E. (2011) Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. British Journal of Clinical Pharmacology, 71(2): 207-223
Bergmann, T.K., Barraclough, K.A., Lee, K.J., Staatz, C.E. (2012) Clinical Pharmacokinetics and Pharmacodynamics of Prednisolone and Prednisone in Solid Organ Transplantation. Clinical Pharmacokinetics, 51(11): 711-741
Borobia, A.M., Romero, I., Jimenez, C., Gil, F., Ramirez, E., de Gracia, R., Escuin, F., Gonzalez, E., Sansuán, A.J.C. (2009) Trough Tacrolimus Concentrations in the First Week After Kidney Transplantation Are Related to Acute Rejection. Therapeutic Drug Monitoring, 31(4): 436-442
Carrasco-Portugal, M.del C., Flores-Murrieta, F.J. (2011) Gender Differences in the Pharmacokinetics of Oral Drugs. Pharmacology, 02(01): 31-41
Chow, F., Jusko, W.J. (2004) Immunosuppressive Interactions among Calcium Channel Antagonists and Selected Corticosteroids and Macrolides Using Human whole Blood Lymphocytes. Drug Metabolism and Pharmacokinetics, 19(6): 413-421
Christians, U., Schmidt, G., Bader, A., Lampen, A., Schottmann, R., Linck, A., Sewing, K. (1996) Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. British Journal of Clinical Pharmacology, 41(3): 187-190
Dai, Y., Hebert, M.F., Isoherranen, N., Davis, C.L., Marsh, C., Shen, D.D., Thummel, K.E. (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metabolism and Disposition, 34(5): 836-47
Dubbelboer, I.R., Pohanka, A., Said, R., Rosenborg, S., Beck, O. (2012) Quantification of Tacrolimus and Three Demethylated Metabolites in Human Whole Blood Using LC–ESI–MS/MS. Therapeutic Drug Monitoring, 34(2): 134-142
Ekberg, H., Bernasconi, C., Noldeke, J., Yussim, A., Mjornstedt, L., Erken, U., Ketteler, M., Navratil, P. (2010) Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrology Dialysis Transplantation, 25(6): 2004-2010
Europeans medicines agency-Committee for Human Medicinal Products (CHMP) (2014) EMA questions and answers: Positions on specific questions addressed to the pharmacokinetics working party. May 02 EMA/618604/2008 Rev. 9. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/WC500002963.pdf
Fasinu, P., Pillay, V., Ndesendo, V.M.K., du Toit, L.C., Choonara, Y.E. (2011) Diverse approaches for the enhancement of oral drug bioavailability. Biopharmaceutics & Drug Disposition, 32(4): 185-209
Gabardi, S., Olyaei, J.A. (2008) Solid organ transplantation. u: Chisholm-Burns M.A., Schwinghammer T.L., Wells B.G., Malone P.M., Kolesar J.M., Dipiro J.T. [ur.] Pharmacotherapy Principles and Practice, New York: McGraw Hills Companies, Inc, p. 939-64
Hebert, M. (1999) Diltiazem increases tacrolimus concentrations. Annals of Pharmacotherapy, 33(6): 680-682
Holford, N.H.G. (2001) Target concentration intervention: beyond Y2K. British Journal of Clinical Pharmacology, 52: 55-59
Hosohata, K., Masuda, S., Ogura, Y., Oike, F., Takada, Y., Katsura, T., Uemoto, S., Inui, K. (2008) Interaction between Tacrolimus and Lansoprazole, but not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5. Drug Metabolism and Pharmacokinetics, 23(2): 134-138
Hugger, E.D., Audus, K.L., Borchardt, R.T. (2002) Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. Journal of Pharmaceutical Sciences, 91(9): 1980-1990
Itagaki, F., Homma, M., Takara, K., Ohnishi, N., Yokoyama, T., Sakaeda, T., Yagami, T., Kobayashi, H., Okamura, N., Kohda, Y. (2004) Effect of Rabeprazole on MDR1-Mediated Transport of Rhodamine 123 in Caco-2 and Hvr100-6 Cells. Biological & Pharmaceutical Bulletin, 27(10): 1694-1696
Iwasaki, K. (2007) Metabolism of Tacrolimus (FK506) and Recent Topics in Clinical Pharmacokinetics. Drug Metabolism and Pharmacokinetics, 22(5): 328-335
Kahan, B.D., Keown, P., Levy, G.A., Johnston, A. (2002) Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther, 24(3): 330-50; discussion 329
Kershner, R.P., Fitzsimmons, W.E. (1996) Relationship of fk506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation, 62(7): 920-926
Kidney disease: Improving global outcomes (KDIGO) transplant work group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant, 9 Suppl 3: S1-155
Krensky, M.A., Bennett, M.W., Vincenti, F. (2011) Immunosuppressants, tolerogens and immunostimulants. u: Brunton L.L., Blumenthal D.K., Murri N., Dandan R.H., Knollmann B.C. [ur.] Goodman & Gilman's the pharmacological Basis of Therapeutics, New York: McGraw-Hill Book Company, 12th ed. p. 1005-31
Leroy, S., Fargue, S., Bensman, A., Deschênes, G., Jacqz-Aigrain, E., Ulinski, T. (2011) Tacrolimus adverse events in transplant recipients with diarrhoea or calcium channel blockers: Systematic review. Medical Case Studies, 2(7): 58-68
Leroy, S., Isapof, A., Fargue, S., Fakhoury, M., Bensman, A., Deschênes, G., Jacqz-Aigrain, E., Ulinski, T. (2010) Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics. Pediatric Nephrology, 25(5): 965-969
Lew, K.H., Ludwig, E.A., Milad, M.A., Donovan, K., Middleton, E., Ferry, J.J., Jusko, W.J. (1993) Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clinical Pharmacology and Therapeutics, 54(4): 402-414
Li, J., Wang, X., Chen, S., Liu, L., Fu, Q., Chen, X., Teng, L., Wang, C., Huang, M. (2010) Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics Journal, 11(4): 300-306
Li, W., Zeng, S., Yu, L., Zhou, Q. (2013) Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag, 9: 259-71
Mcevoy, G.K. (2011) AHFS drug information 2011. Bethesda, MD: American Society of Health-System Pharmacists
Miura, M., Inoue, K., Kagaya, H., Satoh, S., Tada, H., Sagae, Y., Habuchi, T., Suzuki, T. (2007) Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharmaceutics & Drug Disposition, 28(4): 167-175
Passey, C., Birnbaum, A.K., Brundage, R.C., Oetting, W.S., Israni, A.K., Jacobson, P.A. (2011) Dosing equation for tacrolimus using genetic variants and clinical factors. British Journal of Clinical Pharmacology, 72(6): 948-957
Pleym, H., Spigset, O., Kharasch, E.D., Dale, O. (2003) Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiologica Scandinavica, 47(3): 241-259
Press, R.R., Ploeger, B.A., Hartigh, J.den, van der Straaten, T., van Pelt, J., Danhof, M., de Fijter, J.W., Guchelaar, H. (2009) Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients. Therapeutic Drug Monitoring, 31(2): 187-197
Provenzani, A. (2013) Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World Journal of Gastroenterology, 19(48): 9156
Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., Komano, T. (1993) Human P-glycoprotein transports cyclosporin A and FK506. Journal of Biological Chemistry, 268(9): 6077-80
Schwartz, J.B. (2003) The Influence of Sex on Pharmacokinetics. Clinical Pharmacokinetics, 42(2): 107-121
Shihab, F.S., Lee, S.T., Smith, L.D., Woodle, E.S., Pirsch, J.D., Gaber, A.O., Henning, A.K., Reisfield, R., Fitzsimmons, W., Holman, J., First for the Astellas Corticosteroid Withdrawal (2012) Effect of Corticosteroid Withdrawal on Tacrolimus and Mycophenolate Mofetil Exposure in a Randomized Multicenter Study. American Journal of Transplantation, 13(2): 474-484
Soldin, O.P., Mattison, D.R. (2009) Sex Differences in Pharmacokinetics and Pharmacodynamics. Clinical Pharmacokinetics, 48(3): 143-157
Staatz, C. (2001) Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrology Dialysis Transplantation, 16(9): 1905-1909
Stratta, P., Quaglia, M., Cena, T., Antoniotti, R., Fenoglio, R., Menegotto, A., Ferrante, D., Genazzani, A., Terrazzino, S., Magnani, C. (2011) The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. European Journal of Clinical Pharmacology, 68(5): 671-680
Sweetman, S.C. (2011) Martindale: The complete drug reference. London: Pharmaceutical Press, 37
Taber, D.J., Dupuis, R.E. (2013) Kidney and liver transplantation. u: Alldredge B.K., Corelli R.L., Ernst M.E., Guglielmo B.J., Jacobson P.A., Kradjan W.A., et al [ur.] Applied therapeutics: The clinical use of drugs, Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 10th ed. p. 827-60
Takahashi, K. (2004) Lansoprazole-Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism. Annals of Pharmacotherapy, 38(5): 791-794
Takahashi, K., Yano, I., Fukuhara, Y., Katsura, T., Takahashi, T., Ito, N., Yamamoto, S., Ogawa, O., Inui, K. (2007) Distinct Effects of Omeprazole and Rabeprazole on the Tacrolimus Blood Concentration in a Kidney Transplant Recipient. Drug Metabolism and Pharmacokinetics, 22(6): 441-444
Terrazzino, S., Quaglia, M., Stratta, P., Canonico, P.L., Genazzani, A.A. (2012) The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients. Pharmacogenetics and Genomics, 22(8): 642-645
Thervet, E., Anglicheau, D., King, B., Schlageter, M.H., Cassinat, B., Beaune, P., Legendre, C., Daly, A.K. (2003) Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12. Transplantation, 76(8): 1233-1235
Undre, N.A. (2003) Pharmacokinetics of tacrolimus-based combination therapies. Nephrology Dialysis Transplantation, 18(90001): 12i-15
Vavic, N., Rancic, N., Dragojevic-Simic, V., Draskovic-Pavlovic, B., Bokonjic, D., Ignjatovic, L., Mikov, M. (2013) The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study. European Journal of Drug Metabolism and Pharmacokinetics, 39(4): 243-253
Velickovic-Radovanovic, R.M., Paunovic, G., Mikov, M., Djordjevic, V., Stojanovic, M., Catic-Djordjevic, A., Cvetkovic, T. (2010) Clinical Pharmacokinetics of Tacrolimus after the First Oral Administration in Renal Transplant Recipients on Triple Immunosuppressive Therapy. Basic & Clinical Pharmacology & Toxicology, 106(6): 505-510
Velickovic-Radovanovic, R., Mikov, M., Catic-Djordjevic, A., Stefanovic, N., Mitic, B., Paunovic, G., Cvetkovic, T. (2014) Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients. European Journal of Drug Metabolism and Pharmacokinetics, 40(1): 95-102
Velickovic-Radovanovic, R., Mikov, M., Catic-Djordjevic, A., Stefanovic, N., Stojanovic, M., Jokanovic, M., Cvetkovic, T. (2012) Tacrolimus as a Part of Immunosuppressive Treatment in Kidney Transplantation Patients: Sex Differences. Gender Medicine, 9(6): 471-480
Velicković-Radovanović, R., Mikov, M., Paunović, G., Djordjević, V., Stojanović, M., Cvetković, T., Catić-Djordjević, A. (2011) Gender Differences in Pharmacokinetics of Tacrolimus and Their Clinical Significance in Kidney Transplant Recipients. Gender Medicine, 8(1): 23-31
Venkataramanan, R., Swaminathan, A., Prasad, T., Jain, A., Zuckerman, S., Warty, V., McMichael, J., Lever, J., Burckart, G., Starzl, T. (1995) Clinical Pharmacokinetics of Tacrolimus. Clinical Pharmacokinetics, 29(6): 404-430
Wallemacq, P., Armstrong, V.W., Brunet, M., Haufroid, V., Holt, D.W., Johnston, A., Kuypers, D., Meur, Y.L., Marquet, P., Oellerich, M., Thervet, E., Toenshoff, B., Undre, N., Weber, L.T., Westley, I.S. (2009) Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. Therapeutic Drug Monitoring, 31(2): 139-152
Wolbold, R., Klein, K., Burk, O., Nüssler, A.K., Neuhaus, P., Eichelbaum, M., Schwab, M., Zanger, U.M. (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 38(4): 978-988
Zhao, W., Baudouin, V., Fakhoury, M., Storme, T., Deschênes, G., Jacqz-Aigrain, E. (2012) Pharmacokinetic Interaction Between Tacrolimus and Amlodipine in a Renal Transplant Child. Transplantation, 93(7): e29-e30
Zuo, X., Zhou, Y., Zhang, B., Yang, G., Cheng, Z., Yuan, H., Ouyang, D., Liu, S., Barrett, J.S., Li, P., Liu, Z., Tan, H., Guo, R., Zhou, L., Xie, Y., Li, Z., Li, J., Wang, C. (2013) Effect of CYP3A5*3 Polymorphism on Pharmacokinetic Drug Interaction between Tacrolimus and Amlodipine. Drug Metabolism and Pharmacokinetics, 28(5): 398-405
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/vsp140905005r
objavljen u SCIndeksu: 16.10.2015.
metod recenzije: dvostruko anoniman

Povezani članci

Nema povezanih članaka